PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+7.42%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$176M
AUM Growth
+$3.3M
(+1.9%)
Cap. Flow
-$3.52M
Cap. Flow
% of AUM
-2%
Top 10 Holdings %
Top 10 Hldgs %
34.97%
Holding
113
New
8
Increased
24
Reduced
32
Closed
7
Avg Time Held
3.2
years
Top 10 Avg Time Held
1.9
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRXH
SRX Global
SRXH
|
+$1.26M |
| 2 |
Achieve Life Sciences
ACHV
|
+$1.25M |
| 3 |
Biolase, Inc.
BIOL
|
+$1.09M |
| 4 |
Vivos Therapeutics
VVOS
|
+$1.06M |
| 5 |
ASPU
ASPEN GROUP, INC.
ASPU
|
+$1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vericel Corp
VCEL
|
+$4.36M |
| 2 |
Biora Therapeutics, Inc. Common Stock
BIOR
|
+$1.92M |
| 3 |
SHSP
SharpSpring, Inc.
SHSP
|
+$1.79M |
| 4 |
DNA X Inc
SONM
|
+$1.49M |
| 5 |
INTRUSION INC NEW
INTZ
|
+$1.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.07% |
| 2 | Technology | 17.16% |
| 3 | Communication Services | 6.71% |
| 4 | Industrials | 4.61% |
| 5 | Consumer Staples | 4.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CareDx
CDNA
$3.38B
| $9.39M | 5.33% |
102,642
-3,500
| -3% | -$278K |
2017 Q3
15 quarters
|
|
2
OptimizeRx
OPRX
$156M
| $7.21M | 4.09% |
116,430
-5,276
| -4% | -$268K |
2018 Q2
12 quarters
|
|
3
NeoGenomics
NEO
$2.16B
| $7.15M | 4.06% |
158,300
-2,500
| -2% | -$111K |
2013 Q2
32 quarters
|
|
4
Natera
NTRA
$57.1B
| $7.09M | 4.02% |
62,450
-1,500
| -2% | -$153K |
2018 Q2
12 quarters
|
|
5
Idexx Laboratories
IDXX
$41.4B
| $7.01M | 3.98% |
11,105
| – | – |
2013 Q3
31 quarters
|
|
6
Axogen
AXGN
$2.08B
| $5.9M | 3.35% |
272,840
-4,650
| -2% | -$94K |
2013 Q3
31 quarters
|
|
7
Veracyte
VCYT
$3.48B
| $5M | 2.84% |
124,980
-1,500
| -1% | -$64.1K |
2018 Q1
13 quarters
|
|
8
DELISTED
FlexShopper
FPAY
| $4.39M | 2.49% |
1,479,370
+100,000
| +7% | +$265K |
2018 Q3
11 quarters
|
|
|
CSLT
9
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $4.29M | 2.44% |
1,633,000
+173,500
| +12% | +$323K |
2020 Q3
3 quarters
|
|
10
Microsoft
MSFT
$3.96T
| $4.2M | 2.38% |
15,493
| – | – |
2014 Q1
29 quarters
|
|
|
11
Vericel Corp
VCEL
$2.05B
| $4.13M | 2.34% |
78,612
-76,495
| -49% | -$4.36M |
2014 Q3
27 quarters
|
|
12
Inuvo
INUV
$7.83M
| $4M | 2.27% |
414,751
+36,490
| +10% | +$293K |
2018 Q2
12 quarters
|
|
13
DELISTED
Streamline Health Solutions
STRM
| $3.43M | 1.95% |
129,197
-2,706
| -2% | -$80.5K |
2018 Q2
12 quarters
|
|
14
DELISTED
Cantaloupe
CTLP
| $3.3M | 1.87% |
277,975
-1,250
| -0.4% | -$14.7K |
2020 Q4
2 quarters
|
|
15
Standard BioTools
LAB
$254M
| $3.21M | 1.82% |
520,825
-20,000
| -4% | -$107K |
2017 Q4
14 quarters
|
|
16
Abbott
ABT
$178B
| $3.2M | 1.81% |
27,580
| – | – |
2014 Q1
29 quarters
|
|
17
LeMaitre Vascular
LMAT
$1.89B
| $3.16M | 1.79% |
51,800
-1,950
| -4% | -$104K |
2017 Q1
17 quarters
|
|
18
Eli Lilly
LLY
$1.08T
| $3.15M | 1.79% |
13,708
| – | – |
2013 Q2
32 quarters
|
|
19
AtriCure
ATRC
$2.91B
| $3.04M | 1.73% |
38,350
| – | – |
2013 Q2
32 quarters
|
|
20
Exagen
XGN
$205M
| $3M | 1.71% |
200,480
-3,050
| -1% | -$46.8K |
2019 Q3
7 quarters
|
|
21
DELISTED
Avinger, Inc. Common Stock
AVGR
| $2.91M | 1.65% |
7,888
+2,118
| +37% | +$734K |
2018 Q4
10 quarters
|
|
22
Alphatec Holdings
ATEC
$1.61B
| $2.71M | 1.54% |
176,750
-7,000
| -4% | -$108K |
2019 Q3
7 quarters
|
|
23
Digi International
DGII
$2.7B
| $2.55M | 1.45% |
126,800
-1,500
| -1% | -$28.2K |
2020 Q1
5 quarters
|
|
24
Rockwell Medical
RMTI
$31M
| $2.52M | 1.43% |
25,224
-578
| -2% | -$59.6K |
2013 Q2
32 quarters
|
|
25
Ooma
OOMA
$548M
| $2.44M | 1.38% |
129,225
+9,425
| +8% | +$171K |
2018 Q2
12 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Perkins Capital Management held 113 positions worth $176M, up 1.9% from $173M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Perkins Capital Management's Q2 2021 filing shows 8 new, 24 increased, 32 reduced and 7 closed positions. Its largest new stake was SRX Global: 153 shares worth $1.29M. The largest sale was Vericel Corp, an estimated $4.36M.
By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 66% a quarter earlier, followed by Technology and Communication Services.
- Perkins Capital Management's largest Q2 2021 buy was SRX Global: 153 shares worth $1.29M.
- Perkins Capital Management added most to Achieve Life Sciences in Q2 2021, an estimated $1.25M increase.
- Perkins Capital Management's biggest Q2 2021 reduction was Vericel Corp, cutting an estimated $4.36M.
- Perkins Capital Management fully exited Biora Therapeutics, Inc. Common Stock in Q2 2021, selling an estimated $1.92M.
- Perkins Capital Management's ten largest holdings make up 35% of its $176M portfolio in Q2 2021.
- Perkins Capital Management opened 8 new positions and closed 7 in Q2 2021.
- Perkins Capital Management's portfolio value rose 1.9% quarter-over-quarter to $176M.
Based on Perkins Capital Management's 13F filing for Q2 2021, filed 28 Jul 2021.